Spatiotemporal strategies to identify aggressive biology in precancerous breast biopsies by Frankhauser, David E. et al.
F O CU S A R T I C L E
Spatiotemporal strategies to identify aggressive biology in
precancerous breast biopsies
David E. Frankhauser1 | Tijana Jovanovic-Talisman1 | Lily Lai1 |
Lisa D. Yee1 | Lihong V. Wang2 | Ashish Mahabal3 | Joseph Geradts4 |
Russell C. Rockne1 | Jerneja Tomsic1 | Veronica Jones1 |
Christopher Sistrunk1 | Gustavo Miranda-Carboni5 | Eric C. Dietze1 |
Loretta Erhunmwunsee1 | Terry Hyslop6 | Victoria L. Seewaldt1
1Department of Population Sciences, City
of Hope Comprehensive Cancer Center,
Duarte, California
2Department of Medical Engineering,
California Institute of Technology,
Pasadena, California
3Center for Data Driven Discovery,
California Institute of Technology,
Pasadena, California
4Department of Pathology, Duke
University, Durham, North Carolina
5Department of Hematology and
Oncology, University of Tennessee,
Memphis, Memphis, Tennessee
6Department of Biostatistics, Duke
University, Durham, North Carolina
Correspondence
Victoria L. Seewaldt, Department of
Population Sciences, City of Hope
National Medical Center, 1500 East
Duarte Road, Duarte, CA 91010.
Email: vseewaldt@coh.org
Funding information
National Cancer Institute, Grant/Award
Numbers: 3U01CA189283-S1, P20
CA24619, P30CA033572, R01CA170851,
R01CA192914, R01CA220693, T32
CA221709, U01CA189283
Abstract
Over 90% of breast cancer is cured; yet there remain highly aggressive breast
cancers that develop rapidly and are extremely difficult to treat, much less
prevent. Breast cancers that rapidly develop between breast image screening
are called “interval cancers.” The efforts of our team focus on identifying
multiscale integrated strategies to identify biologically aggressive precancer-
ous breast lesions. Our goal is to identify spatiotemporal changes that occur
prior to development of interval breast cancers. To accomplish this requires
integration of new technology. Our team has the ability to perform single
cell in situ transcriptional profiling, noncontrast biological imaging, mathe-
matical analysis, and nanoscale evaluation of receptor organization and sig-
naling. These technological innovations allow us to start to identify
multidimensional spatial and temporal relationships that drive the transi-
tion from biologically aggressive precancer to biologically aggressive interval
breast cancer.
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1 | INTRODUCTION
The precursor lesion(s) for biologically aggressive breast cancers are poorly understood. Currently, the clinical
aggressiveness of a precancerous breast lesion is primarily evaluated based on epithelial cell morphology (normal-
< hyperplasia < atypia < ductal carcinoma in situ [DCIS] < invasive cancer). While morphology is important, pre-
cancerous lesions are clinically assessed at a single time point and on morphology alone, which may not always
account for the future biological potential of a precancerous lesion. For example, a 1.0 cm, node-negative, estrogen
receptor/progesterone receptor-positive (ER/PR+) HER2-wild type lesion in an 80-year-old woman is treated more
aggressively than atypical ductal hyperplasia in a 30-year-old germline BRCA1 mutation carrier. Yet, the 30-year-old
BRCA1 mutation carrier (relative to the 80-year-old woman) has a much higher 5-year probability of developing met-
astatic breast cancer.
Currently there is a need to re-think our approach to evaluating precancerous breast lesions and screening for
biologically aggressive breast cancer. Despite nationwide mammography screening programs to decrease mortality
from breast cancer by increasing early detection, it is not possible to identify which patients diagnosed with atypical
biopsies will progress to develop breast cancer. Both the genetic basis for cancer and the multi-hit hypothesis are well
supported, but it remains unclear how individual genetic alterations affect the tissue ecosystem, how spatial microen-
vironments are organized with heterogeneous populations of cell types, and how the evolution of the molecular sig-
natures in these cells in precancerous lesions drive tumor initiation. Understanding the genetic, epigenetic, and
transcriptional basis of this transition within the native spatial context is critical to stratify patients for the develop-
ment of personalized medicine approaches to pair patients with the most appropriate interventional strategies based
on their specific prognosis.
2 | CURRENT CHALLENGES
2.1 | Standard of care guidelines do not adequately account for biology
Breast cancer is a diverse collection of diseases with distinct biology, rate of progression, and prognosis. Despite the het-
erogeneity of breast cancer as a disease, our strategies for screening and early detection are not tailored to the likely
biology of the cancer in question. For example, current National Comprehensive Cancer Network guidelines recom-
mend the same imaging plans for women who harbor a germline BRCA2- versus BRCA1-mutation (yearly screening
mammography and breast magnetic resonance imaging) (Bevers et al., 2018). These uniform imaging plans are rec-
ommended despite the fact that women with germline BRCA2 mutations typically develop average prognosis estrogen
receptor-positive (ER+) breast cancer and women with BRCA1 mutations most frequently develop biologically aggres-
sive triple-negative breast cancers (TNBC) (Ha et al., 2017; Joosse, 2012). Ultimately, our screening approach is success-
ful at detecting biologically indolent disease but frequently fails at early detection of biologically aggressive cancers.
2.2 | Precancerous breast lesions—over reliance on DCIS
DCIS has been extensively studied as a precursor lesion. DCIS is easy to identify on mammography, has a long lead-
time, and has defined morphology. However, it is doubtful that DCIS is representative of aggressive biology. Even when
DCIS progresses to invasion, the resulting invasive breast cancer typically carries a good prognosis (20 year survival is
97%) (Narod, Iqbal, Giannakeas, Sopik, & Sun, 2015). Furthermore, a DCIS intermediate is rarely (<15%) identified for
the majority of biologically aggressive cancers (Bryan, Schnitt, & Collins, 2006). It is hypothesized that biologically
aggressive breast cancers progress so rapidly as to preclude capture of a DCIS precursor lesion.
2.3 | Spatial progression—does breast cancer evolve from a focal mass or high-risk
field?
In 1996, Helene Smith first proposed the concept of a “high risk field”—that breast cancer arose in a damaged lobule
(or lobules) containing molecular changes that allowed the survival of a “second-hit” (Deng, Lu, Zlotnikov, Thor, &
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Smith, 1996). It is not clear, even today, whether breast cancer arises from a focal mass (conventional model) or a bio-
chemically damaged breast lobule. If aggressive breast cancers arise from a focal mass, then the best strategy for early
detection is high resolution imaging. Conversely, if aggressive breast cancers arise from a high-risk field, then the best
approach is to develop biologically based imaging to detect the damaged lobule.
2.4 | Contribution of tissue inflammation and need for metabolic imaging
While the association between obesity and postmenopausal, estrogen receptor-positive (ER+) breast cancer is well
established, the association between obesity, inflammation, and pre-menopausal breast cancer remains controversial,
particularly in Black/African American women (Yee, Mortimer, Natarajan, Dietze, & Seewaldt, 2020). One potential
confounding factor is that body mass index (BMI) and body composition (muscle to adipose tissue ratio) differs between
race and ethnicity (Gomez-Ambrosi et al., 2012; Okorodudu et al., 2010). It is known that elevated adipose tissue is
associated with (a) inflammation of breast white adipose and (b) is associated with adipocyte hypertrophy and cell
death leading to chronic, subclinical inflammation of adipose tissue (Iyengar et al., 2019). There has also been a focus
on metabolic health; individuals with elevated BMI can be metabolically healthy; conversely individuals with a low or
normal BMI can be metabolically unhealthy and insulin-resistant (Iyengar et al., 2017). Insulin activates AKT/mTOR-
as well as Ras/Raf/cMYC-signaling—pathways that are involved in predicting aggressive breast cancer biology (Yee
et al., 2020). These studies highlight the importance of being able to image the metabolic state of at-risk and cancerous
breast tissue.
2.5 | Importance of immune cell signaling and immunotherapy
The last 5 years have brought an increased appreciation of the role of immune cells in cancer initiation and response to
targeted immune therapy. While there has been significant progress in developing targeted immunotherapy for many
cancer types, progress in breast cancer has been limited. Breast cancers are considered to be immunologically “cold”
(quiescent) and exhibit (a) low lymphocyte infiltration and (b) poor response to anti-PD-1/PD-L1 therapy (Gatti-Mays
et al., 2019). Tumor and immunologic profiling of the breast tumor microenvironment has identified key immune com-
ponents and potential mechanisms that immune-cell subset promote evasion to immune therapy. Therapeutic strategies
to increase breast cancer response to immunotherapy are reviewed by Gatti-Mays et al. and include (a) expand effector
T-cells, natural killer cells, and immunostimulatory dendritic cells, (b) increase the effectiveness of antigen presenta-
tion, and (c) decrease inhibitory cytokines, M2 tumor-associated macrophages, and myeloid derived suppressor cells
(Gatti-Mays et al., 2019). While all three strategies hold promise, there is a need to be able to rapidly and in real-time
(a) characterize the in situ signaling networks that promote a “cold” microenvironment in the breast and (b) determine
whether strategies to “warm” the “cold” microenvironment have been successful. Our goal is to develop strategies that
can identify in situ immune cell signaling networks and provide real-time metabolic imaging of tissue inflammation
and response to targeted prevention and therapy.
3 | CANCER INITIATION
3.1 | What is the time scale for initiation and progression of aggressive breast cancers?
Currently, we have a poor understanding of the timescale over which biologically aggressive breast cancers evolve.
From 2005 to 2014 we enrolled 656 underserved high-risk women in a disparities breast MRI screening trial. All women
had greater than 20% lifetime risk for breast cancer and clinically qualified for breast MRI screening by American Can-
cer Society Guidelines (Saslow et al., 2007). The racial distribution of these 656 women was: 347 (53%) White, 292 (44%)
Black, 14 (2.1%) Asian, 3 (<1%) Native American/Pacific Islander; the ethnic distribution was 98% (648%) non-Hispanic
and 8 (2%) Hispanic. From 2005 to 2014, 41 women developed invasive breast cancer; the stage of presentation was
28 (68%) Stage 1, 13 (32%) Stage 2–3, and 0 (0%) Stage 4. Our serial MRI screening studies provide evidence that while
some breast cancers progressed slowly over time (Figure 1a), other breast cancers rapidly progressed and metastasized
(Figure 1b).
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3.2 | How early can aggressive biology be detected?
Interval breast cancers are cancers that develop within the recommended screening interval. Of the 656 high-risk women
participating in our MRI screening trial, 41 women developed an invasive interval breast cancer; of these women, 6 had
an abnormal MRI but a normal follow-up biopsy within 6 months of developing an interval breast cancer. These individ-
uals provide an opportunity to retrospectively evaluate signaling proteins expressed in the breast biopsy that preceded the
development of an interval cancer. Retrospective analysis of the six paired interval cancer and preceding morphologically
normal breast tissue demonstrated, by immunohistochemistry (IHC), increased expression of Wnt signaling proteins
including Wnt10B, HMGA2 (High Mobility Group AT-Hook 2), and EZH2 (Enhancer of Zest2) (Figure 2).
Wnt proteins are a family of signaling molecules involved in normal embryologic development and dysregulated in
many biologically aggressive cancers, including breast, lung, and colon cancer (Wend et al., 2013). Gene profiling shows
that Wnt is frequently activated in TNBC, particularly in the highly aggressive basal-like and mesenchymal-like sub-
types (El Ayachi et al., 2019; Wend et al., 2013). Wnt10B-signaling is activated in >90% of TNBC and Wnt10B-activation
(unlike Wnt1, Wnt7) predicts poor survival in women with TNBC. We have previously shown that Wnt10B/beta-
catenin transcriptionally activates HMGA2. Wnt10B and HMGA2 co-activate EZH2 and activated HMGA2/EZH2
drives a positive feedback loop that further increases EZH2 expression (El Ayachi et al., 2019). Previous studies show
that EZH2 regulates stem-cell maintenance, cancer initiation, and chemotherapy resistance (Kleer et al., 2003).
Our study is limited by a small number of interval cancers (n = 6); currently a multi-center prospective study is
underway to evaluate the biology of interval cancers. Despite its limitations, our study provides evidence that morpho-
logically normal breast tissue can express proteins such as Wnt10B/EZH2 that are associated with aggressive breast can-
cer biology.
3.3 | Current challenges
Our breast MRI studies provide evidence that some breast cancers progress slowly, but others progress rapidly and
metastasize. In limited studies, we observe by IHC that rapid progression of interval cancers is preceded by expression
of Wnt-signaling proteins in morphologically normal tissue. This raises the question of whether, in rapidly progressing
breast cancers, biochemical abnormalities precede the development of morphological changes (e.g., atypia). To answer
this question, we are currently enrolling high-risk women in a prospective MRI screening trial in high-risk women that
aims to evaluate the frequency of Wnt-activation in morphologically normal tissue prior to development of an interval
cancer. In developing this trial, it was clear that we needed to incorporate analytic tools with the ability to evaluate the
precancerous microenvironment. We anticipate that in incorporating new analytic tools for breast cancer early detec-
tion we will offer strategies for early detection of additional tumor types. Key questions:
FIGURE 1 Screening breast MRI imaging of slowly progressing (a) versus rapidly progressing interval (b) breast cancer. (a) Slowly
progressing ER/PR+ HER2-wild-type breast cancer; arrow at 36 months indicates when breast cancer was first observed, however at that
time, it was too small for our clinical team to biopsy; arrow at 48 months demonstrates slow growth of the tumor over the 12 month interval;
the breast cancer was biopsied at that point, staging revealed a T1N0M0 indolent breast cancer (b) Rapidly progressing ER/PR− HER2-wild-
type triple negative breast cancer (TNBC), 0 months is a normal MRI, at 6 months a change in MRI patterning was observed, this was one of
our first bilateral screening MRI and our team did not recognize the importance of this change and recommended a 6 month follow-up,
biopsy at 12 months (see arrows) demonstrated a T2N0M0 TNBC, the woman underwent bilateral mastectomy and chemotherapy, she is
currently alive and disease free
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1. What are the spatiotemporal cell–cell interactions (epithelial, stromal, immune cells) in the precancerous microenvi-
ronment that drive biologically aggressive breast cancers?
2. Can the spatial and temporal organization of cell surface receptors identify aggressive biology and predict chemo-
therapy resistance?
3. Can early biology be imaged with high-resolution but without contrast or radiotracers?
4 | SINGLE-CELL APPROACHES TO IDENTIFY AGGRESSIVE BIOLOGY
Loss of normal tissue organization is a hallmark of invasive breast cancer and one of the earliest changes observed dur-
ing breast cancer initiation. In the mammary gland, epithelial cells organize within the epithelial compartment and ori-
ent relative to the basement membrane. Stromal cells organize in the stromal compartment with the basement
FIGURE 2 Matched MRI guided biopsy and MRI imaging demonstrates Wnt10B, HMGA2, and EZH2 expression in both
morphologically normal biopsy at 0 months and follow up MRI imaging at 6 months. (a) 36-Year-old high-risk premenopausal woman and
(b) 61-year-old high-risk woman had an abnormal screening MRI at 0 months and 6 months MRI follow-up. For both women, biopsy at
0 months demonstrated morphologically normal tissue that had high expression of Wnt10B/HMGA2/EZH2; 6 month follow-up biopsy
demonstrated TNBC that also expressed high levels of Wnt10B/HMGA2/EZH2, both women had multiple lymph nodes that contained
invasive TNBC but no metastatic disease. After greater than 5 years follow-up both women are alive and disease free
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membrane serving as the dividing line. It is also recognized that interactions between immune cells and epithelial/stro-
mal cells play an important role in cancer initiation, progression, and response to therapy. Currently very little is
known about the role of immune cell signaling/inflammation in promoting breast cancer initiation.
The dynamic interplay between epithelial, stromal, and immune cells governs normal mammary gland architecture.
Loss of these normal regulatory cell–cell signals is hypothesized to play a key role in cancer initiation and progression.
Currently there are many approaches developed, or in development, to evaluate gene expression and chromatin expres-
sion in single cells—both to understand cancer initiation and progression of aggressive cancer biology.
4.1 | Single-cell transcriptome analysis
First reported in 2009, single-cell RNA sequencing (scRNAseq) provides in-depth transcript analysis of single isolated cells.
scRNAseq has rapidly revolutionized understanding of temporal processes such as cell differentiation and malignant transfor-
mation (Suva & Tirosh, 2019). Key to scRNAseq's power for in depth analysis is its adaptability; scRNAseq has been adapted
for variant detection, DNA methylation, chromatin structure, and multi-omic analysis (Stark, Grzelak, & Hadfield, 2019).
The rapid adoption and success of scRNAseq are also due to the development of user-friendly computational tools
for analyzing single cell data. These computational tools allow the user to quantify and interpret expression for each
captured cell (Stark et al., 2019). Methods to analyze transcript expression include: (a) dimensionality reduction for
visually representing the transcriptome of thousands of cells in two to three dimensions (tSNE and UMAP) (McInnes,
Healy, & Melville, 2018; van der Maaten & Hinton, 2008), (b) supervised and unsupervised clustering methods and
marker gene identification for identifying transcriptionally similar cell types (TSCAN, SIMLR, MetaNeighbor) (Crow,
Paul, Ballouz, Huang, & Gillis, 2018; Ji & Ji, 2016; B. Wang et al., 2018), and (c) pseudotime trajectories for ordering
cells based on biological processes (Monocle, PAGA) (Trapnell et al., 2014; Wolf et al., 2019).
Single cell analysis has great power to evaluate the temporal evolution of cell lineage and tissue heterogeneity in
both normal and malignant tissue. However, current techniques are limited because, to perform the analysis, tissue
must first be dispersed into single cells. In dispersing tissue into single cells, spatial organization of the microenviron-
ment (spatial environment) is lost. The spatial environment consists of cell–cell interactions, organization, and signal-
ing. These interactions play a vital role in cancer initiation and progression. Consequently, new in situ techniques have
recently been developed to evaluate the transcriptome of single cells without disrupting tissue structure and organiza-
tion, particularly in the study of tissue inflammation, immune cell-signaling, and cancer initiation and progression.
4.2 | In situ single cell profiling
Recently, several approaches have been developed to provide spatial analysis of gene expression and chromatin struc-
ture in single cells. These single cell spatial approaches are reviewed below. Each technique holds promise, but is lim-
ited either by low resolution or lack of commercialization. It is anticipated, in the near future, that these approaches
will grow in their sophistication and become more accessible to investigators.
4.3 | In situ scRNAseq
This technique provides spatial analysis by physical transfer of nuclear material from individual cells within a tissue
slice to a slide for analysis (Rodriques et al., 2019; Salmén et al., 2018; Stahl et al., 2016). To perform analysis, a tissue
slice is applied to a slide coated with oligo spot or DNA barcoded beads, RNA or DNA is released and analyzed relative
to the spatial location of the original cell. This in situ single cell analysis tool, Spatial Transcriptomics, is commercially
available from ×10 Genomics and has been tested in breast cancer biopsy specimens (Stahl et al., 2016). The limitations
of Spatial Transcriptomics are that (a) tissue sections cannot exceed 7 mm2 in size and (b) the RNA capture spots
(100 μm diameter) significantly exceed the diameter of a single cell (10 μm diameter). A second in situ method pro-
posed by Rodrigues et al., called Slide-seq, provides significantly improved spatial resolution (10 μm) (Rodriques et al.,
2019). A third approach, Geo-seq uses spatially targeted laser capture microdissection (LCM) (J. Chen et al., 2017). The
disadvantages of Geo-seq are that the protocol is time consuming and requires access to a spatially targeted LCM system
(J. Chen et al., 2017; Stark et al., 2019).
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4.4 | seqFISH
Single molecule fluorescence in situ hybridization (smFISH)28,29 has been used for over 15 years to visualize and quan-
tify RNA and DNA in single cells, in situ, in tissue sections. However, smFISH is insufficient for transcript profiling
due to a limited number of fluorophores and channels. First reported in 2012, Dr Long Cai's lab has developed a general
method to highly multiplex single molecule in situ mRNA imaging called sequential FISH (seqFISH) (Figure 3) and
has the capacity to profile hundreds of genes in situ (Lubeck & Cai, 2012; Lubeck, Coskun, Zhiyentayev, Ahmad, &
Cai, 2014). Building upon smFISH, seqFISH uses a temporal barcoding scheme that relies on a limited set of
fluorophores and scales exponentially with time. Specifically, sequential probe hybridizations on the mRNAs in fixed
cells impart a unique predefined temporal sequence of colors, generating in situ mRNA barcodes. The multiplex capac-
ity scales as FN, where F is the number of fluorophores and N is the number of rounds of hybridization. Thus, one can
increase the multiplex capacity by increasing the number of rounds of hybridization with a limited pool of fluorophores.
With 4 fluorophores, 256 genes can be multiplexed with 4 rounds of hybridization.
4.5 | Use of seqFISH to identify aggressive biology in precancerous breast tissue
Currently, Dr Long Cai is applying seqFISH for the first time in a cancer-related setting. One key advantage of seqFISH
is that it enables multi-modal data collection in the same sample with the native spatial structure of the tissue preserved
without disruption or dissociation. In addition to mRNA, seqFISH30 can also simultaneously evaluate introns in single
cells in situ (intron seqFISH). Introns often appear only near transcription active sites and are rapidly degraded
FIGURE 3 Schema depicting the use of seqFISH for evaluating transcript expression in biopsy tissue. (a) Biopsy tissue is obtained and
preserved. (b) Tissue undergoes successive rounds of mRNA hybridization and probe stripping. (c) Transcripts are identified by specific bar
code identification (BRCA1 and BRCA2 are used as illustrations. (d) Transcript expression is analyzed for each transcript in each cell using
unsupervised hierarchical clustering. (e) Cells are classified based on expression pattern, a color assigned for each cell type, and the tissue
architecture is reconstructed. (f) Keynode proteins are validated by IHC
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posttranscription. Thus, the short-lived nature of intron measurements informs the instantaneous transcriptional pro-
gram that the cells are executing. Recent work, called RNA velocity (La Manno et al., 2018), showed that the intron to
exon ratio can predict the differentiation directions of the cell. Techniques like seqFISH provide power to evaluate
changes in the precancerous microenvironment. seqFISH has the ability to simultaneously evaluate early changes in
cell–cell paracrine signaling and evaluate the spatiotemporal dynamics of the earliest changes in cancer initiation—
potentially even before substantial morphological changes occur.
5 | NANOSCALE CELL SURFACE RECEPTOR ORGANIZATION
5.1 | Super resolution microscopy
The wavelength of visible light (250 nm) was once thought to be an insurmountable limit for microscopy. This barrier
has been surpassed by the development of super resolution microscopy (SRM) technologies. SRM now provides <1 nm
resolution of cellular organization and can be used to investigate receptor signaling. SRM, in combination with fluores-
cent tags, allows for measurement of spatiotemporal dynamics of specific DNA and RNA molecules as well as proteins.
Many SRM techniques exist; each SRM technique has specific strengths and weaknesses. Selecting the appropriate
SRM technique requires careful consideration of the experimental question being asked. The tradeoffs between the cur-
rently available methods involve: (a) lateral and axial resolution limits, (b) depth of image (thickness of sample),
(c) time to collect an image, and (d) photodamage (Schermelleh et al., 2019). A number of recent reviews outline the
available SRM techniques in terms of their strengths and limitations and can help guide researchers in the selection of
a SRM technique (Sage et al., 2019; Schermelleh et al., 2019; Sigal, Zhou, & Zhuang, 2018).
5.2 | Predicting aggressive biology and chemotherapy-resistance in a real-time clinical
setting
Single molecule localization microscopy (SMLM) is an SRM approach in which blinking fluorescent molecules are local-
ized with nanoscale precision. Dr Tijana Jovanovic-Talisman has pioneered the development and application of quantita-
tive SMLM (qSMLM) for investigation of receptors in patient tissue samples (Jorand et al., 2016; Tobin et al., 2018).
We detected HER2 in patient samples with fluorescently labeled trastuzumab (Figure 4a). This therapeutic antibody
allowed us to directly detect the HER2 extracellular domain. Labeled samples were imaged using direct optical stochas-
tic reconstruction microscopy (dSTORM) with an optimized acquisition protocol (Tobin et al., 2018). An example
dSTORM image of HER2 positive cell is shown in Figure 4b (top) a diffraction limited image of the same cell stained
with antibody against epithelial marker, cytokeratin 7, is shown in Figure 4b (bottom). The qSMLM readout obtained
on the extracellular HER2 domain may be clinically relevant. Trastuzumab does not bind to constitutively active variant
FIGURE 4 Touch prep-qSMLM for imaging of HER2 in breast cancer tissues. (a) Scheme of HER2 receptor detected using
fluorescently labeled trastuzumab. Alexa Fluor 647 was the fluorophore used in this case. (b) Image of HER2 positive breast cancer patient
cell. Top, red signal represents localizations of Alexa Fluor 647 labeled trastuzumab detected with dSTORM. Bottom, gray signal represents
signal from anti-cytokeratin 7 antibody detected with diffraction limited microscopy. Scale bar, 5 μm. (c) Average detected HER2 density
obtained with touch prep-qSMLM versus HER2 copy number obtained from FISH. For six patients, the correlation coefficient was 0.979 with
95% CI [0.813, 0.998] with a p-value of .0007. Image adapted from Tobin et al. (2018)
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of HER2 with truncated extracellular domain; patients harboring this variant have worse outcome (Saez et al., 2006;
Scaltriti et al., 2007). Other poor responders have a diminished pool of the sterically accessible extracellular HER2 epi-
tope (Mercogliano et al., 2017).
Quantification of qSMLM provides real-time information on receptor density and clustering across the membranes.
Additionally, we can assess receptor heterogeneity. Importantly, we have shown that HER2 copy numbers from FISH
had a significant positive correlation with detected densities from touch prep-qSMLM (Tobin et al., 2018) (Figure 4c).
5.3 | Real-time evaluation of aggressive biology
The application of qSMLM to cancer research has promise to increase our understanding of receptor signaling and
localization during cancer initiation. Increasing evidence suggests that receptor localization may play a key role in
defining aggressive biology and chemotherapy resistance. The advantage of qSMLM is that it can provide real-time eval-
uation (6 hr) of receptor biology in a small clinical sample (touch-prep).
Currently we are using qSMLM to evaluate aggressive biology in luminal B breast cancers (ER+/HER2-wt or
-amplified, Ki67 > 14%). The majority of luminal B breast cancers carry a good prognosis. However, there is a subset of
luminal B breast cancers that are biologically aggressive and highly lethal. These aggressive luminal B breast cancers
disproportionately impact young Black/African American and Hispanic/Latina women of African ancestry (Jemal, Cen-
ter, DeSantis, & Ward, 2010; Ooi, Martinez, & Li, 2011; Serrano-Gomez et al., 2016, 2017).
In luminal B breast cancer, membrane receptors such as HER2, HER3, and EGFR (HER1) can reside and interact
within cholesterol enriched domains, thus creating activated receptor platforms that support rapid signaling
(Gueguinou et al., 2015; Marquez & Pietras, 2001). Upon ligand binding, these activated receptors phosphorylate
RAS/ERK/AKT kinases (Ades et al., 2014; Gueguinou et al., 2015; Marquez & Pietras, 2001; Pietras et al., 1995) and can
upregulate c-MYC (Z. Chen, Wang, Warden, & Chen, 2015; Kerkhoff et al., 1998; R. Sears et al., 2000; R. C.
Sears, 2004). Studies of luminal B breast cancers have identified two key drivers of aggressive biology in women of Afri-
can ancestry: (a) c-myc (MYC) (Naab et al., 2018) and (b) HER2/pAKT-coactivation (Y. Wu et al., 2008). We are cur-
rently using touch prep-qSMLM to assess the role of IGF1R-HER2 interaction in driving aggressive luminal B biology.
qSMLM is being used in a research setting in Black and Latina women with luminal B breast cancer to define HER2/
IGF1R density and colocalization as a means to drive drug development and new therapeutic approaches.
6 | REAL-TIME HUMAN NONCONTRAST BIOLOGICAL IMAGING
6.1 | Limitations of current imaging for early detection
Breast MRI has significantly improved high-risk breast cancer screening. However, MRI has significant limitations.
MRI is expensive and requires the use of gadolinium intravenous contrast agents that can cause hepatorenal syndrome
(Perazella, 2008), permanent deposition in the brain (Ibrahim, Froberg, Wolf, & Rusyniak, 2006), and anaphylaxis
(Ramalho & Ramalho, 2017). Furthermore, while MRI is highly sensitive, MRI has limited specificity. Due to high sen-
sitivity and low specificity, many women undergoing high-risk breast MRI screening require follow-up MRI imaging,
second-look ultrasound, and biopsy. The vast majority of MRI-generated biopsies do not identify cancer, but still
require expensive follow-up. The follow-up is required because while we can determine that (a) an MRI is “abnormal”
and (b) the resultant MRI-generated biopsy is “not cancer,” we are unable to determine the future biological potential
of the “not cancerous” biopsy. Our study of high-risk women previously described above (Figure 2) provides evidence
that some MRI-detected non-cancerous biopsies demonstrate activation of signaling pathways that predict aggressive
biology in invasive cancer. There is a need for new imaging techniques that can rapidly and reproducibly image early
aggressive cancer biology without the need for intravenous contrast agents.
6.2 | Optical imaging and photoacoustic computed tomography
Optical imaging uses light (photons) to activate endogenous molecules (e.g., NADH and hemoglobin) within living cells
and tissues. No contrast injection is required. Optical imaging holds great promise for early detection of aggressive
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biology. Until recently, high-resolution optical imaging could not be used for breast imaging because the penetration is
limited to 1–2 mm.
Photoacoustic computed tomography (PACT) is a novel noncontrast imaging technique that combines endogenous
optical contrast with ultrasonic spatial resolution in a single imaging system (Razansky et al., 2009; Xia, Yao, &
Wang, 2014). PACT holds promise to provide high-resolution optical (endogenous) imaging of deep tissues. Several
PACT systems have been developed that employ a variety of light illumination and detection schemes (Ermilov
et al., 2009; Fakhrejahani et al., 2015; Heijblom, Piras, et al., 2015; Ke, Erpelding, Jankovic, Liu, & Wang, 2012; Kitai
et al., 2014; Kruger et al., 2013; X. Li, Heldermon, Yao, Xi, & Jiang, 2015; Toi et al., 2017; D. Wang et al., 2017). These
systems have advanced PACT technology, but clinical implementation has been blocked by a number of technical chal-
lenges. These technical challenges include: (a) insufficient penetration depth to accommodate most breast sizes and
skin colors, (b) inadequate spatial resolution to image detailed vascular patterns, (c) lack of high temporal resolution to
minimize motion artifacts and enable dynamic or functional studies, (d) minimal limited-view artifacts, and
(d) insufficient noise-equivalent sensitivity and contrast-to-noise ratio to detect breast masses (Ermilov et al., 2009;
Fakhrejahani et al., 2015; Heijblom, Piras, et al., 2015; Heijblom, Steenbergen, & Manohar, 2015; Ke et al., 2012; Kitai
et al., 2014; Kruger et al., 2013; Toi et al., 2017; D. Wang et al., 2017).
6.3 | Recent advancements in PACT imaging
Dr Lihong Wang and associates, as pioneers in the development and translation of PACT for breast imaging (Yao,
Xia, & Wang, 2016), recently reported a significant advancement in breast PACT technology, single breath-hold PACT
(SBHPACT) (Lin et al., 2018). SBHPACT overcomes the five technical challenges listed above that have impeded imple-
mentation of PACT imaging. The resolution of SHB-PACT is approximately four times greater than the resolution of
contrast-enhanced MRI (Lehman & Schnall, 2005). SBHPACT has the capacity to obtain (a) an entire 2D cross-sectional
breast image within 150 μs or (b) a volumetric 3D image of the entire breast within a single breath-hold (15 s).
SBHPACT provides dynamic imaging and delivers high image quality (Lin et al., 2018). Capitalizing on the optimized
illumination method and signal amplification, SBHPACT achieves sufficient noise-equivalent sensitivity to clearly
reveal detailed angiographic structures both inside and outside breast tumors without the use of exogenous contrast
agents (Lin et al., 2018).
6.4 | SHBPACT breast imaging
In published pilot studies, Dr Wang used SBHPACT to image both normal volunteers and women with breast cancer
(Yao et al., 2016). In initial studies, SBHPACT identified eight of nine breast tumors by delineation of vascular density
and architecture. To improve on the interpretation of images, an algorithm was developed to highlight tumors automat-
ically (Yao et al., 2016). At such high spatiotemporal resolutions, SBHPACT is able to differentiate arteries from veins
by detecting blood flow-mediated arterial deformation at the heartbeat frequency. Breast cancers were identified by
SBHPACT, even occult cancers that were not identified by mammography (Yao et al., 2016). Taking advantage of the
high imaging speed, Dr Wang used elastographic SBHPACT to identify the only (1 of 9) tumor missed by angiographic
SHBPACT (Figure 5; adapted from Yao et al., 2016); this innovation improved the sensitivity for breast cancer (Yao
et al., 2016).
6.5 | Promise of SBHPACT for spatiotemporal imaging
SBHPACT has the power to detect the earliest temporal and spatial biological changes that precede development of bio-
logically aggressive cancers. In our studies of high-risk women undergoing annual breast MRI screening (2005–2014;
Figure 2) described above, we observe that clinical neovascularization frequently precedes development of biologically
aggressive breast cancer. PACT readily identifies neo-vascularization with substantially higher resolution than breast
MRI. Since PACT relies on endogenous signaling (no contrast), PACT can be used to serially track the spatiotemporal
events that occur during cancer initiation, particularly, neovascularization. PACT also has promise in detecting tissue
inflammation and potentially could be used to monitor immune cell activation and response to immunotherapy.
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7 | MULTISCALE INTEGRATION OF SPATIOTEMPORAL INFORMATION
7.1 | Multiscale integration
In the “big data” age of cancer research, it is increasingly common for multiple data types to be generated for the same
patient or patient cohort. Integration of multiple different data types (imaging, −omics, microscopy, clinical data, etc.)
for the purpose of addressing a research question is described as multiscale integration. Multiscale integration is moti-
vated by the fact that cancer is ultimately one process in a complex biological system. Cancer evolves over both space
and time, and the effects of cancer span from atomic-scale interactions to macro-scale organization of tissues. There-
fore, to investigate the system wide effects of cancer, multiple data types that cover the scope of a cancer's effects are
needed. Disparate data types provide unique and complementary information as they are obtained from different tech-
nologies, experimental techniques, time points, and spatial scales (micro- vs. macro-scale). Data types that are more
complementary to each other contain more independent information; however, the tradeoff is that data types that are
more independent are often more challenging to develop successful integration strategies.
FIGURE 5 Example of SBHPACT imaging of a cancerous breast. (a) Mammogram of the affected breasts; white circle identified the
breast cancer (RCC right cranial-caudal, RML right medio-lateral). (b) Depth-encoded vascular breast imaging acquired by SBHPACT.
(c) Maximum amplitude projection (MAP) images of thick slices in sagittal planes marked by white dashed lines in (b). (d) Automatic tumor
detection on vessel density map. Background images in gray scale are the MAP of vessels deeper than the nipple. Maps of the relative area
change during breathing in the regions outlined by blue dashed boxes in the angiographic images (e) Elastographic study of the affected
breast
FIGURE 6 Current multi-modality schema for
evaluating aggressive biology in precancerous and
cancerous breast tissue. qSMLM, quantitative-single
molecule localization microscopy; SBHPACT, single
breath-holding photoacoustic computed tomography;
seqFISH, sequential fluorescence in situ hybridization
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7.2 | Defining multiscale integration strategies
Multiscale integration seeks to extract the independent information from each data type that is relevant to the research
question. This task is non-trivial as the data types involved can rarely be quantified in a way that allows direct harmoni-
zation. Mathematical and information theoretic approaches are helpful in determining how two data types are depen-
dent (Ritchie, Holzinger, Li, Pendergrass, & Kim, 2015). Integration is typically performed by identifying or structuring
the data with respect to an outcome or an explanatory variable. Computer learning algorithms have emerged as a prom-
ising avenue as a general multiscale integration framework (Y. Li, Wu, & Ngom, 2018). Artificial intelligence algorithms
are a good fit for data integration because they can agnostically select the aspects of the data that are most informative
to a particular research question.
8 | CONCLUSION
Currently, we lack integrated strategies to identify spatiotemporal events surrounding cancer initiation and progression.
With the evolution of targeted immunotherapy, there is the need for real-time tools to monitor immune microenviron-
ment activation. We anticipate that the addition of new analytic tools such as seqFISH, qSMLM, and SBHPACT will
provide us with the ability to evaluate early events in the precancerous and malignant microenvironment (Figure 6).
Unlike breast MRI, SBHPACT can be repeated multiple times over a span of hours, allowing for real-time evaluation of
metabolism (e.g., following oral glucose administration), and rapid assessment of response to prevention agents and
agents that modify immune cell activation. It is our hope that integration of these new tools can provide a roadmap for
early identification of aggressive biology, not just in breast cancer but for other tumor types.
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